Benjamin Douglas Liu

Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description apt70190-sup-0001-DataS1.docWord document, 220.5 KB Data S1. References 1, , , and , “Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss,” JAMA 330, no. 18 (2023): 1795–1797, https://doi.org/10.1001/jama.2023.19574. 2 ICH, “Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0,” (2024), https://www.meddra.org.

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. GASTROESOPHAGEAL REFLUX DISEASE OBESITY GLUCAGEN-LIKE PEPTIDES BARRETT'S OESOPHAGUS We express our gratitude to Quast and Meier1 for their meticulous assessment of our recent publication.